Personal Products company Honasa Consumer announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Q4FY25 revenue stood at Rs 534 crore, achieving double digit growth with 13.3% YoY, significantly ahead of the FMCG market. The business continues to grow efficiently, delivering a Rs 25 crore PAT and EBITDA stood at 5.1% in Q4FY25, reflecting stronger operational performance. Gross profit margin improved to 70.7% in Q4FY25, up 76 bps YoY, driven by an improved product mix and operational efficiencies The direct distribution-led strategy is strengthening reach, with over 1 lakh unique outlets billed in FY25 and direct distributor contribution surging from 38% in FY24 to 71% in Q4FY25. FY25 Financial Highlights: Revenue from Operations stood at Rs 2,066 crore for FY25 compared to Rs 1,919 crore PAT stood at Rs 72 crore for FY25 compared to Rs 110 crore for FY24 Varun Alagh, Chairman and CEO & Co-founder, Honasa Consumer said, “FY25 has been a year of learnings, focus, and disciplined execution. Despite its ups and downs, we’ve seen green shoots emerge, with the business delivering double-digit growth and strong momentum across our key brands. In Q4FY25, we achieved revenue of Rs 534 crore, growing 13.3% YoY—significantly ahead of the broader FMCG market. Mamaearth’s strategic pivot has begun to show results, with double-digit category growth across e-Commerce and Modern Trade, driven by building leadership in focus categories, optimized media mix modeling, and awareness-led brand building. NielsenIQ data reaffirms this shift—Mamaearth has gained share across key categories, entered the Top 5 in face wash market share. Our newer brands have also maintained a strong trajectory, growing over 30% YoY in FY25. Notably, The Derma Co. has now crossed Rs 100 crore ARR from offline channels while continuing to lead across top online platforms. As we scale, our vision remains clear—building Honasa into a future-ready house of brands through disruptive innovation, deeper offline penetration, and consumer-centric offerings. We’re not just creating brands that lead today, but shaping the future of India’s beauty and personal care landscape.” Result PDF
Conference Call with Emcure Pharmaceuticals Ltd. Management and Analysts on Q4FY25 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Ircon International Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Commodity Chemicals company Deepak Fertilisers & Petrochemicals Corporation announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: The company demonstrated continued growth, achieving a notable 28% increase in revenues for the quarter, reaching Rs 2,667 crores EBITDA for Q4 increased by 10%, amounting to Rs 480 crore Net Profit: An impressive 21% jump in Q4 Bulk Fertilizers manufactured sales volume in Q4 surged by 68% YoY, driven by increased adoption of our innovative crop focus nutrient solution. Our speciality product, LDAN, saw an impressive 11% YoY growth in sales volume in Q4FY25, FY25 Financial Highlights: Annual revenue growth stood at 18% with record of Rs 10,274 crore for FY25 EBITDA experienced significant growth of 50%, reaching Rs 1,925 crore. Full year PAT doubled, amounting to Rs 945 crore. Remarkable growth visible with revenue share from specialty products improving from 17% in FY24 to 22% in FY25. Strategic investments remain on track – the overall progress in TAN project in Gopalpur is at 75%, and the same for Nitric Acid project in Dahej is at 48%. During FY25, team achieved a significant milestone by surpassing 1 Million MT in bulk fertilizer sales and liquidation for the first time, demonstrating the team’s focus and effective execution of strategic products with scale. Our speciality product, LDAN, saw a notable 15% YoY increase for the entire fiscal year. Despite Capex spent of Rs 655 crore in FY25, net debt reduced from Rs 3,426 crore to Rs 3,305 crore based on healthy cash generation. Net debt to EBIDTA reduced from 2.66x to 1.72x on YoY basis. Reflecting on the company’s performance, S.C. Mehta, Chairman and Managing Director of DFPCL, stated: "This year has been challenging yet transformative, marked by strategic actions that boosted growth across all product segments. Our financial performance for FY 2024–25 highlights resilience, innovation, and a strong foundation for future success. Outlook: With an above-average monsoon forecast, we expect robust Kharif season demand for crop-specific solutions. Mining Chemicals growth from FY25 is likely to continue into FY26, driven by increasing power demand and infrastructure investments. The health sector is projected to expand, supported by government and private initiatives, boosting our Pharma / Specialty Chemicals portfolio." Result PDF